Psilocybin and human longevity
npj Aging April 3, 2026 DOI: 10.1038/s41514-026-00380-y via OpenAlex
Summary
AI-generated from the abstractA small study compared mortality among prominent psychedelic personalities, researchers, and advocates who claimed psychedelic use (11 people) with cancer researchers (12 people) and aging researchers (5 people). All groups lived longer than the general population, which the authors attribute to socioeconomic advantage rather than psychedelic use. Psychedelic personalities did not outlive the other researcher groups. The findings underscore the need for rigorous mechanistic and epidemiological studies before inferring human anti-aging effects of psychedelics.
Study at a glance
| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 28 |
| Population | Prominent psychedelic personalities, researchers, and advocates; cancer researchers; aging researchers |
| Topics | Psilocybin |
| Keywords | Longevity Population Human life Epidemiology |
| Key finding | Psychedelic personalities did not outlive cancer and aging researchers, and all groups exceeded population life expectancy, likely due to socioeconomic advantage. |
Abstract
Psilocybin extends lifespan in aged mice, and this has prompted extensive media speculation about possible human longevity benefits. We examined mortality among prominent psychedelic personalities, researchers, and advocates who claimed psychedelic use (n = 11) and compared them with cancer (n = 12) and aging researchers (n = 5). All groups exceeded population life expectancy, reflecting the effect of socioeconomic advantage on lifespan, but psychedelic personalities did not outlive cancer and aging researchers. These findings highlight the need for rigorous mechanistic and epidemiological studies before inferring human anti-aging effects of psychedelics.